Re-evaluating therapeutic neovascularization

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Clinical Trials

Background:

• Exogenous growth factors enhance neo-vascularization in animal models.
• Small clinical studies showed promise, but two large trials yielded negative results.
• Hypoxia and inflammation are key stimuli for neo-vascularization, involving Hypoxia-Inducible-Factor (HIF-1).

Purpose of the Study:

• To analyze the reasons for the failure of recent large clinical trials on neo-vascularization.
• To explore alternative therapeutic strategies for ischemic tissue repair.
• To investigate the mechanisms of arteriogenesis for future therapeutic development.

Main Methods:

• Review of existing literature on neo-vascularization and arteriogenesis.
• Analysis of potential factors contributing to clinical trial failures.
• Discussion of mechanistic insights into angiogenesis and arteriogenesis.

Main Results:

• Angiogenesis is primarily hypoxia-dependent, while arteriogenesis is driven by inflammation and hemodynamic factors.
• Numerous factors, including patient selection, therapy choice, dosing, and trial design, may explain trial failures.
• Current understanding of arteriogenesis mechanisms is limited compared to angiogenesis.

Conclusions:

• The therapeutic focus should shift from angiogenesis to arteriogenesis for ischemic tissue repair.
• Further research, including genetic studies and population studies, is needed to understand arteriogenesis.
• Redefining clinical trial endpoints is crucial for advancing therapies for vascularization.